Clinical Trials Directory

Trials / Unknown

UnknownNCT01611493

Osseotite Certain Prevail for the Preservation of Crestal Bone

A Prospective, Randomized-Controlled Evaluation of the Osseotite CP4 Certain Prevail Tapered Implant for the Preservation of Crestal Bone

Status
Unknown
Phase
Phase 3
Study type
Interventional
Enrollment
40 (estimated)
Sponsor
Andres Duque Duque · Academic / Other
Sex
All
Age
18 Years
Healthy volunteers
Not accepted

Summary

A potential complicating factor affecting implants is crestal bone loss. The causes of crestal bone loss are attributed to several factors. Among those hypothesized, proof for one or another cause remains obscure. Clinical documentation suggests that implant design may be a key factor. While the evidence is inconclusive, various authors suggest that it is a result of a combination of effects including (1) limited drilling procedure and restricted second-stage surgery 2, (2) rough implant surface in crestal bone 3, (3) microthread design for implant stiffness 4, (4) loading along a conus versus a flat interface 5, and (5) the absence of a significant microgap 6. The practice of platform switching (e.g. placing a 4 mm diameter abutment on a 5 mm implant seating surface physically moves the inflammatory cell infiltrate zone away from the crestal bone). The growing body of anecdotal platform switch evidence supports this biological width hypothesis. Here the biological width refers to the height of the dento-gingival attachment apparatus around a normal tooth and is defined as the distance necessary for a healthy existence of bone and soft tissue from the most apical extent of a dental restoration. To formally test this hypothesis the current study has been designed. The Prevail implant has been made with an integrated medialized seating surface that establishes a platform switching function. This implant moves the implant/abutment interface away from the crestal bone and may therefore reduce the amount of bone loss observed in the standard (non-medialized) Osseotite implant design. The objective of this study is to evaluate crestal bone levels adjacent to the implant reference point from the time of implant placement to a period of two years after loading.

Conditions

Interventions

TypeNameDescription
DEVICEOsseotite Prevail ImplantOsseotite Prevail will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure
DEVICEOsseotite Non Prevail ImplantOsseotite Non Prevail Implant will be placed in sites with native bone, with at least three months of healing since tooth extraction or four months from bone augmentation grafting procedure

Timeline

Start date
2011-03-01
Primary completion
2012-11-01
Completion
2013-09-01
First posted
2012-06-05
Last updated
2012-06-05

Locations

1 site across 1 country: Colombia

Source: ClinicalTrials.gov record NCT01611493. Inclusion in this directory is not an endorsement.